pharmaceutical-investing Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients
African Discovery Group announces signing of Definitive Sales and Purchase Agreement for Butembo Copper Asset in the Democratic Republic of Congo; name change to Copper Intelligence, Inc
